GANX — Gain Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Gain Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.9 | -17.6 | -22.3 | -20.4 | -20.2 |
| Depreciation | |||||
| Non-Cash Items | 1.89 | 1.32 | 2.88 | 2.53 | 2.61 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.385 | 1.51 | 0.442 | -1.08 | -1.01 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.4 | -14.7 | -18.9 | -18.9 | -18.5 |
| Capital Expenditures | -0.094 | -0.119 | -0.015 | -0.022 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -14.7 | 10.2 | 5 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.094 | -14.8 | 10.2 | 4.98 | — |
| Financing Cash Flow Items | -0.853 | 0 | — | -0.281 | -0.395 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 41.8 | -0.079 | 12.6 | 13 | 28.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.4 | -29.6 | 4.49 | -1.41 | 10.5 |